A global diagnostics company was preparing to launch a new wave of oncology sequencing tests aimed at strengthening its existing portfolio.
These included innovations focused on minimal residual disease (MRD) detection and treatment response monitoring.
They sought expertise to build a strong and scalable pricing and value strategy that could support global market access across both public and private systems, while reinforcing the broader value of the portfolio.
The project required careful consideration of how to demonstrate differentiation, secure stakeholder support, and design a pricing strategy that could be flexible across varied local requirements while staying globally coherent.
We collaborated with the client to develop a pricing and access strategy that would support long-term success across global markets.
We assessed the external environment, reimbursement frameworks, market access conditions and trends, and competitive benchmarks across key geographies. This allowed us to shape the narrative around the clinical and economic value of each product. It was tailored to specific use cases and stakeholder needs, followed by a structured segmentation of markets based on their access conditions.
Drawing on these insights, we developed a portfolio-wide pricing approach, including product-level guidance, and adaptable contracting principles. Our strategy was designed to balance consistency and flexibility, supporting both near-term decisions and future expansion.
The strategy brought greater clarity and consistency to the client’s global pricing decisions.
With a stronger foundation in place, the diagnostics organization is now well positioned to align internally and engage effectively with key stakeholders in priority markets. This enables them to clearly communicate and sustain the portfolio’s value over time.
Contact us
If you’d like to discuss what these changes mean for your business, let’s start a conversation.